PharmaShots | Incisive News in 3 Shots

Subscribe Now

Mabwell

Mabwell Highlights Results from the P-III Study of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology

Mabwell Highlights Results from the P-III Study of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology

February 22, 2024

Mabwell Reports the US FDA’s IND Approval of 7MW3711 for the Treatment of Solid Tumors

Mabwell Reports the US FDA’s IND Approval of 7MW3711 for the Treatment of Solid Tumors

February 21, 2024

Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor

Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor

July 19, 2023

Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

April 3, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us